Medicare AdvantageCoverageMedium impact
MA08.176a, Tarlatamab-dlle (Imdelltra® for intravenous use
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jun 15, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated medical necessity criteria for Tarlatamab-dlle (Imdelltra®), an intravenous cancer medication. This affects billing requirements and prior authorization processes for this specialty oncology drug.
Action Required
By June 15, 2026: Billing team must review and update prior authorization requirements for Tarlatamab-dlle (Imdelltra®) injections according to new medical necessity criteria. Oncology staff should verify updated coverage requirements before administering this IV medication. Claims may be denied if new medical necessity criteria are not met.